MARKET

AEZS

AEZS

Aeterna Zentaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3678
-0.0033
-0.89%
After Hours: 0.3660 -0.0018 -0.49% 19:13 09/18 EDT
OPEN
0.3651
PREV CLOSE
0.3711
HIGH
0.3759
LOW
0.3630
VOLUME
1.27M
TURNOVER
--
52 WEEK HIGH
1.790
52 WEEK LOW
0.3400
MARKET CAP
23.05M
P/E (TTM)
-2.0332
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average AEZS stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AEZS
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AEterna Zentaris Inc. (USA) stock information, including NASDAQ:AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.